Skip to main content

Bone Metastases from Prostate Cancer: From Symptom Control to Pain Palliation

Abstract

Prostate cancer is the second most frequently diagnosed cancer and the fifth leading cause of cancer-related death in men. The majority, around 90 %, of patients with metastatic castration-resistant prostate cancer (mCRPC) have radiological evidence of bone metastases, and bone is the first metastatic site in 80 % of patients [1, 2].

Keywords

  • Prostate Cancer
  • Bone Metastasis
  • Neuropathic Pain
  • Pain Syndrome
  • Cancer Pain

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-42327-2_19
  • Chapter length: 20 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   109.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-42327-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   149.99
Price excludes VAT (USA)
Hardcover Book
USD   149.99
Price excludes VAT (USA)
Fig. 19.1

References

  1. Bubendorf L et al (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31:578–583

    CAS  CrossRef  PubMed  Google Scholar 

  2. Scher HI, Chung LW (1994) Bone metastases: improving the therapeutic index. Semin Oncol 21:630–656

    CAS  PubMed  Google Scholar 

  3. Smith MR et al (2015) Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol 26:368–374

    CAS  CrossRef  PubMed  Google Scholar 

  4. von Moos R, Sternberg C, Body JJ, Bokemeyer C (2013) Reducing the burden of bone metastases: current concepts and treatment options. Support Care Cancer 21:1773–1783

    CrossRef  Google Scholar 

  5. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ (2008) Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26(15):2544–2549

    CrossRef  PubMed  Google Scholar 

  6. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168(3):1005–1007

    CrossRef  PubMed  Google Scholar 

  7. Depuy V et al (2007) Effects of skeletal morbidities on longitudinal patient‑reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869–876

    CrossRef  PubMed  Google Scholar 

  8. Nørgaard M et al (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184:162–167

    CrossRef  PubMed  Google Scholar 

  9. Berry WR, Laszlo J, Cox E et al (1979) Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate. Cancer 44:763–775

    CAS  CrossRef  PubMed  Google Scholar 

  10. Emrich LJ, Priore RL, Murphy GP et al (1985) Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45:5173–5179

    CAS  PubMed  Google Scholar 

  11. Berthold DR, Pond G, De Wit R et al (2006) Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. J Clin Oncol. 24:221s(suppl, abstr 4516)

    Google Scholar 

  12. Armstrong A, Garrett-Mayer ES, Ou Yang YC et al (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX 327 study analysis. Clin Cancer Res 13:6396–6403

    CAS  CrossRef  PubMed  Google Scholar 

  13. Turner SL, Gruenewald S, Spry N, Gebski V; Metastron Users Group (2001) Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 84(3):297–302.

  14. Wang C, Shen Y (2012) Study on the distribution features of bone metastases in prostate cancer. Nucl Med Commun 33(4):379–383

    CrossRef  PubMed  Google Scholar 

  15. Wang CY, Wu GY, Shen MJ, Cui KW, Shen Y (2013) Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas. Oncol Lett 5:391–397

    PubMed  Google Scholar 

  16. Conti G et al (2008) Prostate cancer metastases to bone: observational study for the evaluation of clinical presentation, course and treatment patterns. Presentation of the METAURO protocol and of patient baseline features. Arch Ital Urol Androl 80:59–64

    PubMed  Google Scholar 

  17. Grond S, Zeck D, Diefenbach C et al (1996) Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain 64(1):107–114

    CAS  CrossRef  PubMed  Google Scholar 

  18. Banning A, Sjogren P, Henriksen H (1991) Pain causes in 200 patients referred to a multidisciplinary cancer pain clinic. Pain 45(1):45–48

    CAS  CrossRef  PubMed  Google Scholar 

  19. Caraceni A, Portenoy RK (1999) An international survey of cancer pain characteristics and syndromes. Pain 82:263–274

    CAS  CrossRef  PubMed  Google Scholar 

  20. Middlemiss T, Laird BJ, Fallon MT (2011) Mechanisms of cancer-induced bone pain. Clin Oncol 23:387–392

    CAS  CrossRef  Google Scholar 

  21. Dy SM, Asch SM, Naeim A, Sanati H, Walling A, Lorenz KA (2008) Evidence-based standards for cancer pain management. J Clin Oncol 26:3879–3885

    CrossRef  PubMed  Google Scholar 

  22. Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69:1–18

    CAS  CrossRef  PubMed  Google Scholar 

  23. Løhre ET, Klepstad P, Bennett MI, Brunelli C, Caraceni A, Fainsinger RL, Knudsen AK, Mercadante S, Sjøgren P, Kaasa S; European Association for Palliative Care Research Network (2016) From “Breakthrough” to “Episodic” Cancer Pain? A European Association for Palliative Care Research Network Expert Delphi Survey Toward a Common Terminology and Classification of Transient Cancer Pain Exacerbations. J Pain Symptom Manage. pii:S0885-3924(16)00070-1. doi:10.1016/j.jpainsymman.2015.12.329. [Epub ahead of print]

  24. Davies A, Buchanan A, Zeppetella G, Porta-Sales J, Likar R, Weismayr W et al (2013) Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manage 46:619–628

    CrossRef  PubMed  Google Scholar 

  25. Payne R (1993) Pain management in the patient with prostate cancer. Cancer 71(suppl):1131–1137

    CAS  CrossRef  PubMed  Google Scholar 

  26. Falk S, Dickenson AH (2014) Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol 32:1647–1654

    CAS  CrossRef  PubMed  Google Scholar 

  27. Brunelli C, Bennett MI, Kaasa S, Fainsinger R, Sjøgren P, Mercadante S, Løhre ET, Caraceni A; European Association for Palliative Care (EAPC) Research Network; International Association for the Study of Pain (IASP) Cancer Pain Special Interest Group (2014) Classification of neuropathic pain in cancer patients: a Delphi expert survey report and EAPC/IASP proposal of an algorithm for diagnostic criteria. Pain. 155(12):2707–2713

  28. Basch E (2012) Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health 15:401–403

    CrossRef  PubMed  Google Scholar 

  29. Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S; European Palliative Care Research Collaborative (EPCRC) (2011) Studies comparing Numerical Rating S cales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 41(6):1073–1093

  30. Brunelli C, Zecca E, Martini C, Campa T, Fagnoni E, Bagnasco M, Lanata L, Caraceni A (2010) Comparison of numerical and verbal rating scales to measure pain exacerbations in patients with chronic cancer pain. Health Qual Life Outcomes 8:42

    CrossRef  PubMed  PubMed Central  Google Scholar 

  31. Daut RL, Cleeland C, Flanery RC (1983) Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other disease. Pain 17:197–210

    CAS  CrossRef  PubMed  Google Scholar 

  32. Melzack R (1975) The McGill Pain questionnaire. Major properties and scoring methods. Pain 1:277–299

    CAS  CrossRef  PubMed  Google Scholar 

  33. Fishman B, Pasernak S, Wallenstein SL, Houde R, Holland JC, Foley KM (1987) The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer 60:115–118

    CrossRef  Google Scholar 

  34. Caraceni A (1996) Clinicopathology correlates of common cancer syndromes. Hematol Oncol Clin North Am 10:57–78

    CAS  CrossRef  PubMed  Google Scholar 

  35. World Health Organization (1996) Cancer pain relief, 2nd edn. WHO, Geneva

    Google Scholar 

  36. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F (1987) A validation study of the WHO method for cancer pain relief. Cancer 59:850–856

    CAS  CrossRef  PubMed  Google Scholar 

  37. Kane CM, Hoskin P, Bennett MI (2015) Cancer induced bone pain. BMJ 350:h315

    CrossRef  PubMed  Google Scholar 

  38. Nabal M, Librada S, Redondo MJ et al (2012) The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO step II opioids in the control of pain in advanced cancer. A systemic review of the literature. Palliat Med 26:305–312

    CrossRef  PubMed  Google Scholar 

  39. Vardy J, Agar M (2014) Nonopioid drugs in the treatment of cancer pain. J Clin Oncol 32:1677–1690

    CAS  CrossRef  PubMed  Google Scholar 

  40. Mantyh P (2013) Bone cancer pain: causes, consequences, and therapeutic opportunities. Pain 154:S54–S62

    CrossRef  PubMed  Google Scholar 

  41. McNicol E, Strassels SA, Goudas L, Lau J, Carr DB (2005) NSAIDS or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev (1):CD005180. Review. Update in: Cochrane Database Syst Rev

    Google Scholar 

  42. Center for Disease Control and Prevention, U.S. Department of Health and Human Services (2016) CDC Guideline for prescribing opioids for chronic pain – United States, 2016. Morb Mortal Wkly Rep 65:1–49

    Google Scholar 

  43. Franklyn GM (2014) Opioids for chronic noncancer pain. A position paper of the American Academy of Neurology. Neurology 83:1277–1284

    CrossRef  CAS  Google Scholar 

  44. Portenoy RK (2011) Treatment of cancer pain. Lancet 377:2236–2247

    CAS  CrossRef  PubMed  Google Scholar 

  45. Caraceni A, Hanks G, Kaasa S et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68

    CAS  CrossRef  PubMed  Google Scholar 

  46. Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, Santini D, Cavanna L, Melotti B, Conte PF, Roila F, Cascinu S, Bruera E, Tognoni G, Luppi M (2016) Randomized trial of low-dose morphine versus weak opioids in moderate cancer pain. J Clin Oncol 34(5):436–442

    CAS  CrossRef  PubMed  Google Scholar 

  47. Klepstad P, Kaasa S, Jystad A et al (2003) Immediate- or sustained-release morphine for dose findings during start of morphine to cancer patients: a randomized, double-blind trial. Pain 101:193–198

    CAS  CrossRef  PubMed  Google Scholar 

  48. Caraceni A, Davies A, Poulain P et al (2013) Guidelines for the management of breakthrough pain in patients with cancer. J Natl Compr Canc Netw 11(Suppl 1):S29–S36

    PubMed  Google Scholar 

  49. Shih A, Jackson KC 2nd (2007) Role of corticosteroids in palliative care. J Pain Palliat Care Pharmacother 21(4):69–76, Review

    CrossRef  PubMed  Google Scholar 

  50. Leppert W, Buss T (2012) The role of corticosteroid in the treatment of pain in cancer patients. Curr Pain Headache Rep 16:307–313

    CrossRef  PubMed  PubMed Central  Google Scholar 

  51. Paulsen O, Aass N, Kaasa S et al (2013) Do corticosteroid provide analgesic effects in cancer patients? A systematic literature review. J Pain Symptom Manage 46:6–105

    CrossRef  CAS  Google Scholar 

  52. Paulsen O, Klepstad P, Rosland JH et al (2014) Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: a randomized, placebo-controlled double-blind trial. J Clin Oncol 32:3221–3228

    CAS  CrossRef  PubMed  Google Scholar 

  53. Haywood A, Good P, Khan S et al (2015) Corticosteroids for the management of cancer-related pain in adults (Review). Cochrane Database Syst Rev (4):CD010756

  54. De Santis M, Saad F (2016) Practical guidance on the role of corticosteroids in the treatment of metastatic castration-resistant prostate cancer. Urology. pii: S0090-4295(16)00146-1

    Google Scholar 

  55. Tannock I, Gospodarowicz M, Meakin W et al (1989) Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590–597

    CAS  PubMed  Google Scholar 

  56. Caraceni A, Zecca E, Martini C et al (2008) Gabapentin for breakthrough pain due to bone metastases. Palliat Med 22:392–393

    CAS  CrossRef  PubMed  Google Scholar 

  57. Sjolund KF, Yang R, Lee KH et al (2013) Randomized study of pregabalin in patients with cancer-induced bone pain. Pain Ther 2:37–48

    CrossRef  PubMed  PubMed Central  Google Scholar 

  58. Fallon M, Hoskin PJ, Colvin LA et al (2016) Randomized double-blind trial of Pregabalin versus placebo in conjunction with palliative radiotherapy for cancer-induced bone pain. J Clin Oncol 34:550–556

    CAS  CrossRef  PubMed  Google Scholar 

  59. Mulvey MR, Rolke R, Klepstad P, Caraceni A, Fallon M, Colvin L, Laird B, Bennett MI; IASP Cancer Pain SIG and the EAPC Research Network (2014) Confirming neuropathic pain in cancer patients: applying the NeuPSIG grading system in clinical practice and clinical research. Pain 155(5):859–863

    Google Scholar 

  60. Boland EG, Mulvey MR, Bennett MI (2015) Classification of neuropathic pain in cancer patients. Curr Opin Support Palliat Care 9:112–115

    CrossRef  PubMed  Google Scholar 

  61. Body JJ, Casimiro S, Costa L (2015) Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol 12(6):340–356

    CrossRef  PubMed  Google Scholar 

  62. Parker C et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223

    CAS  CrossRef  PubMed  Google Scholar 

  63. Sartor O et al (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration‐resistant prostate cancer and bone metastases: results from a phase 3, double- blind, randomised trial. Lancet Oncol 15:738–746

    CAS  CrossRef  PubMed  Google Scholar 

  64. Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS (2012) Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 13(12):1210–1217

    CAS  CrossRef  PubMed  Google Scholar 

  65. Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, Forer D, Hirmand M, de Bono JS (2014) Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 15(10):1147–1156

    CAS  CrossRef  PubMed  Google Scholar 

  66. Baron R, Ferrari S, Russel R (2011) Denosumab and bisphosphonates: different mechanism of action and effects. Bone 48:677–692

    CAS  CrossRef  PubMed  Google Scholar 

  67. Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S, Brunelli C, Pigni A, and Caraceni A (2016) Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliat Med 02692163

    Google Scholar 

  68. Saad F et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458–1468

    CAS  CrossRef  PubMed  Google Scholar 

  69. Saad F et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882

    CAS  CrossRef  PubMed  Google Scholar 

  70. Fizazi K et al (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  71. Porter AT et al (1993) Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25:805–813

    CAS  CrossRef  PubMed  Google Scholar 

  72. Oosterhof GO et al (2003) Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 44:519–526

    CAS  CrossRef  PubMed  Google Scholar 

  73. Tannock IF et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    CAS  CrossRef  PubMed  Google Scholar 

  74. Beer TM et al (2007) Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25:669–674

    CAS  CrossRef  PubMed  Google Scholar 

  75. de Bono JS et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    CrossRef  CAS  PubMed  Google Scholar 

  76. Fizazi K et al (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13:983–992

    CAS  CrossRef  PubMed  Google Scholar 

  77. Ryan CJ et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148

    CAS  CrossRef  PubMed  Google Scholar 

  78. Scher HI et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197

    CAS  CrossRef  PubMed  Google Scholar 

  79. Beer TM et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433

    CrossRef  CAS  PubMed  PubMed Central  Google Scholar 

  80. Adami S, Mian M (1989) Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res 116:67–72

    CAS  CrossRef  PubMed  Google Scholar 

  81. Elomaa I, Kylmälä T, Tammela T et al (1992) Effect of oral clodronate on bone pain: a controlled study in patients with metastatic prostatic cancer. Int Urol Nephro 24:159–166

    CAS  CrossRef  Google Scholar 

  82. Kylmälä T, Taube T, Tammela TLJ et al (1997) Concomitant i.v. and oral clodronate in the relief of bone pain – a double blind placebo-controlled study in patients with prostate can- cer. Br J Cancer 76:939–942

    CrossRef  PubMed  Google Scholar 

  83. Smith JA (1989) Palliation of painful bone metastases from pros- tate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 141:85–88

    PubMed  Google Scholar 

  84. Small EJ, Smith MR, Seaman JJ et al (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21:4277–4284

    CAS  CrossRef  PubMed  Google Scholar 

  85. Weinfurt KP, Anstrom KJ, Castel LD et al (2006) Effect of zole- dronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17:986–989

    CAS  CrossRef  PubMed  Google Scholar 

  86. Mitsiades CS, Bogdanos J, Karamanolakis D et al (2006) Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refrac- tory prostate cancer. Anticancer Res 26:3693–3700

    CAS  PubMed  Google Scholar 

  87. Wang F, Chen W, Chen H et al (2013) Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases. Med Oncol 30:657–663

    CrossRef  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Augusto Caraceni .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Caraceni, A., Zecca, E., Formaglio, F., Ricchini, F. (2017). Bone Metastases from Prostate Cancer: From Symptom Control to Pain Palliation. In: Bertoldo, F., Boccardo, F., Bombardieri, E., Evangelista, L., Valdagni, R. (eds) Bone Metastases from Prostate Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-42327-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42327-2_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42326-5

  • Online ISBN: 978-3-319-42327-2

  • eBook Packages: MedicineMedicine (R0)